BRIEF-AstraZeneca announces agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions

AstraZeneca PLC: * ASTRAZENECA PLC - ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS

* ASTRAZENECA PLC - ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS * ASTRAZENECA: IN Q4 2023, CELLECTIS WILL RECEIVE AN INITIAL PAYMENT OF $105M FROM ASTRAZENECA

* ASTRAZENECA: INITIAL EQUITY INVESTMENT OF $80M, AT $5/SHARE, REPRESENTS AN EQUITY STAKE OF C. 22% IN CELLECTIS * ASTRAZENECA: A FURTHER $140M EQUITY INVESTMENT, AT $5/SHARE, IS EXPECTED TO CLOSE IN EARLY 2024

* ASTRAZENECA: CELLECTIS ALSO ELIGIBLE TO GET IND OPTION FEE, OTHER MILESTONE PAYMENTS, RANGING FROM $70M UP TO $220M PLUS TIERED ROYALTIES Source text for Eikon: Further company coverage:

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)